PCOS and Insulin Resistance: The Root Cause Connection

Polycystic ovary syndrome affects roughly 10% of women of reproductive age worldwide, making it the most common hormonal disorder in that group — yet it remains chronically misunderstood, underdiagnosed, and undertreated. At the center of PCOS, for most women who have it, is insulin resistance: a metabolic disruption that drives the symptoms, sustains the cycle, and responds to the right interventions.

What Is PCOS and How Is It Diagnosed?

Polycystic ovary syndrome is a complex endocrine disorder characterized by three hallmark features, two of which must be present for diagnosis under the Rotterdam criteria (the most widely used diagnostic standard):

1. Irregular or absent menstrual cycles — reflecting disrupted ovulation
2. Clinical or biochemical signs of hyperandrogenism — excess male hormones, presenting as acne, excess facial or body hair (hirsutism), or hair thinning on the scalp
3. Polycystic ovarian morphology on ultrasound — multiple follicles on the ovaries (though "polycystic" is a bit of a misnomer; these aren't true cysts)

PCOS is a diagnosis of exclusion, meaning other conditions that can cause similar symptoms — thyroid disease, hyperprolactinemia, congenital adrenal hyperplasia — must be ruled out first. This is part of why diagnosis takes an average of two years and multiple provider visits, which is a genuine failure of the healthcare system for a condition this prevalent.

The symptoms of PCOS extend well beyond the diagnostic criteria. Many women also experience weight gain or difficulty losing weight, fatigue, mood changes, skin darkening (acanthosis nigricans), and fertility challenges. Understanding why all of these symptoms occur together requires understanding what's happening at the hormonal and metabolic level.

The Insulin Resistance–PCOS Connection

Insulin resistance is present in approximately 65–80% of women with PCOS, regardless of body weight. This is one of the most important and least communicated facts about the condition: you don't have to be overweight to have insulin resistance driving your PCOS. Lean women with PCOS have it too, though it tends to be more pronounced and symptomatic in women with higher body weight.

Insulin resistance means the body's cells are less responsive to insulin's signal to take up glucose from the blood. The pancreas compensates by producing more insulin — a state called hyperinsulinemia. Chronically elevated insulin levels have cascading effects throughout the body, but the ones most relevant to PCOS play out in the ovaries and adrenal glands.

How High Insulin Drives PCOS Symptoms

High insulin directly stimulates the ovarian theca cells to produce more androgens — primarily testosterone and androstenedione. At the same time, high insulin suppresses the liver's production of sex hormone-binding globulin (SHBG), the protein that binds and inactivates testosterone in the bloodstream. Less SHBG means more free, biologically active testosterone circulating in the body — which is what drives hirsutism, acne, and scalp hair loss.

Excess androgens also disrupt the normal follicular development cycle in the ovaries. Instead of one follicle maturing and releasing an egg each month, follicles develop partially and then stall — resulting in the ultrasound appearance of multiple small follicles and, more importantly, in irregular or absent ovulation. No ovulation means no regular period and significant fertility challenges.

The connection between insulin and androgen production explains why treating insulin resistance — not just managing symptoms — is central to effective PCOS care. Treating the acne without addressing the hyperinsulinemia is treating a symptom of a symptom. Addressing insulin resistance can improve menstrual regularity, reduce androgen levels, improve fertility, and address the cardiometabolic risks that accumulate over time in women with untreated PCOS.

Long-Term Cardiometabolic Risks

PCOS is not just a reproductive condition — it carries significant long-term health risks that extend well past the childbearing years. Women with PCOS are at substantially elevated risk for type 2 diabetes (risk is three to seven times higher than in women without PCOS), metabolic syndrome, non-alcoholic fatty liver disease, and cardiovascular disease. A 2020 meta-analysis in Human Reproduction Update found that women with PCOS had a 2.4-fold increased risk of developing type 2 diabetes and a 1.5-fold increased risk of cardiovascular events compared to age-matched controls.

These risks are driven largely by the underlying insulin resistance and its downstream effects on lipid metabolism, blood pressure, and inflammatory markers. This underscores why treating PCOS with a cardiometabolic lens — not just a gynecological one — is important for women at any age.

Treatment Approaches: From Metformin to GLP-1 Medications

Effective PCOS treatment has historically been fragmented: oral contraceptives for menstrual regulation, spironolactone for androgen excess, and metformin for insulin resistance. Each of these addresses a piece of the puzzle. But the emergence of GLP-1 receptor agonists — medications like semaglutide and tirzepatide — has opened a new chapter in PCOS treatment, particularly for women with significant insulin resistance and weight-related symptoms.

Metformin: The Original Insulin Sensitizer

Metformin has been used off-label for PCOS for decades and remains a first-line option for women with insulin resistance. It works by reducing glucose production in the liver and improving the sensitivity of peripheral tissues to insulin. In PCOS, it reliably lowers fasting insulin levels, modestly reduces androgen levels, and improves menstrual regularity in many (though not all) women.

Metformin's limitations are real. GI side effects — nausea, diarrhea, bloating — are common, particularly in the first weeks of use. Weight loss is modest at best; studies show average weight reductions of 1–3% in women with PCOS. And for women with significant insulin resistance who need more aggressive metabolic intervention, metformin may be insufficient on its own.

Metformin and GLP-1 medications are not mutually exclusive. Many women continue metformin while adding a GLP-1 agonist, and evidence suggests the combination may be synergistic for both insulin sensitization and weight reduction.

GLP-1 Medications for PCOS: A Growing Evidence Base

The rationale for GLP-1 receptor agonists in PCOS is straightforward: they are among the most effective available tools for improving insulin sensitivity, reducing fasting insulin levels, and producing meaningful weight loss — addressing the root cause of most PCOS symptoms simultaneously.

The clinical evidence has grown substantially in recent years. A 2023 randomized trial published in The Lancet Diabetes & Endocrinology found that semaglutide 1.0 mg weekly in women with PCOS and overweight/obesity produced significantly greater improvements in weight, insulin levels, free androgen index, and menstrual regularity compared to both placebo and lifestyle intervention alone. Participants saw an average 16% reduction in fasting insulin levels and a meaningful reduction in free testosterone after 32 weeks.

A 2024 review in the Journal of Clinical Endocrinology & Metabolism synthesized data from 12 trials of GLP-1 receptor agonists in PCOS and concluded that these medications significantly improved menstrual cycle regularity, reduced androgen levels, improved insulin sensitivity markers, and supported clinically meaningful weight reduction in overweight and obese women with PCOS.

The response in lean women with PCOS is less well-studied but increasingly a focus of research. Even at lower doses that may not be warranted for weight loss specifically, GLP-1 medications' effects on insulin sensitivity and androgen production appear to translate across BMI categories.

What Labs Should You Get?

If you suspect PCOS or have a diagnosis but haven't had a comprehensive metabolic workup, the following labs provide essential information about the degree of insulin resistance and its downstream effects:

• Fasting insulin and fasting glucose — together, these allow calculation of HOMA-IR, the most practical clinical marker of insulin resistance. A HOMA-IR above 2.5 is generally considered indicative of insulin resistance, though some labs use a cutoff of 2.0.
• HbA1c — reflects average blood sugar over the past 3 months and identifies pre-diabetes or diabetes that may exist alongside PCOS.
• Total testosterone and free testosterone — confirms hyperandrogenemia and provides a baseline against which to measure treatment response.
• SHBG — low SHBG is a sensitive marker of insulin resistance and correlates with free androgen excess.
• LH and FSH — an elevated LH:FSH ratio (greater than 2:1) is characteristic of PCOS and reflects the disrupted hormonal signaling from the pituitary gland.
• Lipid panel — women with PCOS frequently have dyslipidemia, particularly elevated triglycerides and low HDL cholesterol, reflecting underlying metabolic dysfunction.
• Thyroid panel (TSH, free T4) — thyroid dysfunction can mimic or worsen PCOS symptoms and should be excluded.

At Truventa Medical, our providers review comprehensive labs as part of the intake process for women with PCOS seeking weight management support. Understanding your metabolic baseline — not just your weight — is how we build a treatment plan that actually addresses the underlying problem.

Lifestyle Strategies That Work for PCOS

Medication is most effective when layered on top of lifestyle strategies that directly address insulin resistance. For PCOS specifically, the following approaches have the strongest evidence base:

Low-Glycemic Eating

Carbohydrates with a high glycemic index produce rapid spikes in blood glucose and insulin — exactly the hormonal environment that drives PCOS symptoms. Switching to a lower-glycemic dietary pattern, emphasizing whole grains, legumes, non-starchy vegetables, lean proteins, and healthy fats, reduces post-meal insulin spikes and supports gradual improvement in insulin sensitivity over weeks to months. Women with PCOS don't need to avoid carbohydrates entirely, but the quality and quantity of carbohydrate choices meaningfully affect the metabolic environment.

Exercise That Prioritizes Insulin Sensitivity

Both aerobic exercise and resistance training improve insulin sensitivity, but they do so through different mechanisms and can be combined for maximum effect. Aerobic exercise (walking, cycling, swimming) increases glucose uptake in muscle cells during and after exercise. Resistance training builds muscle mass, which is the body's primary site of insulin-mediated glucose disposal — more muscle means more capacity to clear glucose from the blood without large insulin spikes. Two to three sessions of resistance training per week plus 150 minutes of moderate aerobic activity are achievable goals that have measurable effects on PCOS symptoms over 8–12 weeks.

Sleep and Stress Management

Chronic sleep deprivation worsens insulin resistance and elevates cortisol — which in turn drives androgen production. Women with PCOS already have higher baseline cortisol reactivity than women without the condition, making sleep and stress management particularly important. Prioritizing 7–9 hours of quality sleep and incorporating evidence-based stress reduction strategies (mindfulness, structured relaxation, counseling) can meaningfully improve the metabolic environment even before significant weight loss occurs.

Finding the Right Provider

PCOS management is inherently multidisciplinary — it touches gynecology, endocrinology, nutrition, and mental health. Finding a single provider who can hold all of these threads together, or a coordinated team, can be challenging. Telehealth has meaningfully expanded access in this space by making it easier for women to connect with providers who have experience and interest in PCOS management without geographic barriers.

Truventa Medical's providers approach PCOS with a metabolic-first framework: understanding that addressing insulin resistance is the lever most likely to improve symptoms across the board. If you've been managing PCOS with birth control or topical treatments alone — and you're still struggling with weight, fatigue, or irregular cycles — a conversation about insulin-sensitizing strategies, including GLP-1 medications, may open doors that weren't available to you before.